If you're obese and have heart disease but not diabetes, taking semaglutide might lower your chances of having a serious heart problem by 20%.
From Lizard Venom Regrows 'Irreplaceable' Cartilage · videoSee the scientific wording
Semaglutide reduces the incidence of major adverse cardiovascular events by 20% in individuals with obesity and established cardiovascular disease who do not have type 2 diabetes.
There's disagreement
Randomized trialsThe 4 studies we reviewed point in different directions — there's no clear consensus.
What the research says
4 studies reviewedSupporting (3)
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Randomized Controlled TrialHuman2023
The study tested semaglutide in people with obesity and heart disease but no diabetes, and found it reduced heart problems by 20%, just like the claim says.
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Randomized Controlled TrialHuman2024
The study looked at kidney health but also confirmed that semaglutide reduced heart problems by 20% in people with obesity and heart disease who don’t have diabetes, which is exactly what the claim says.
Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.
Computational/Algorithm Study2025
The study looks at semaglutide in people with obesity and heart disease but no diabetes, and says it helps reduce serious heart problems, which matches the claim.
Contradicting (1)
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%
Randomized Controlled TrialHuman2024
The study found semaglutide was linked to 20% fewer heart problems compared to placebo, but the actual benefit for most people is small—only 1.5% fewer events—and many stopped taking it due to side effects.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 3 supporting, 1 contradicting studies
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
If you're obese and have heart disease but not diabetes, taking semaglutide might lower your chances of having a serious heart problem by 20%.
Evidence from Studies
Supporting (3)
Community contributions welcome
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
The study tested semaglutide in people with obesity and heart disease but no diabetes, and found it reduced heart problems by 20%, just like the claim says.
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
The study looked at kidney health but also confirmed that semaglutide reduced heart problems by 20% in people with obesity and heart disease who don’t have diabetes, which is exactly what the claim says.
Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.
The study looks at semaglutide in people with obesity and heart disease but no diabetes, and says it helps reduce serious heart problems, which matches the claim.
Contradicting (1)
Community contributions welcome
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%
The study found semaglutide was linked to 20% fewer heart problems compared to placebo, but the actual benefit for most people is small—only 1.5% fewer events—and many stopped taking it due to side effects.
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Randomized Controlled Trials on Semaglutide and Cardiovascular Outcomes in Non-Diabetic Obese Patients with Cardiovascular Disease
Systematic review of RCTs assessing semaglutide vs. placebo in non-diabetic obese adults with established cardiovascular disease, reporting MACE (cardiovascular death, non-fatal MI, non-fatal stroke) over ≥2 years.
Double-Blind, Placebo-Controlled Trial of Semaglutide on Cardiovascular Outcomes in Obese Adults with Cardiovascular Disease and No Diabetes
Randomized, double-blind, placebo-controlled trial in obese adults (BMI ≥30) with prior CVD, no type 2 diabetes, followed for ≥3 years to assess MACE incidence.
Prospective Cohort Study of Semaglutide Use and Cardiovascular Event Rates in Obese Patients with Heart Disease Without Diabetes
Longitudinal cohort of obese individuals with CVD and no diabetes, comparing those prescribed semaglutide vs. not, tracking MACE over time with adjustment for confounders.
Case-Control Study of Semaglutide Exposure in Obese Patients with Cardiovascular Disease and No Diabetes: MACE as Outcome
Matched case-control study where cases are obese, non-diabetic CVD patients who had MACE, controls are similar patients without MACE, comparing prior semaglutide exposure.
Prevalence of Major Adverse Cardiovascular Events in Obese, Non-Diabetic Cardiovascular Disease Patients Using Semaglutide
Cross-sectional analysis of a national health database assessing current semaglutide use and history of MACE in obese adults with CVD and no diabetes.